secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001193125-24-189932
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%
----------------------------------------------------------------------------

- Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.
- Adjusted EBITDA $20M, margin 23% vs 17.4% in Q2 2023.
- CEO reports competitive pressure from high-priced skin substitutes causing employee and customer attrition.
- Launched HELIOGEN (first xenograft) and commenced RCT for EPIEFFECT.
- Cash $69M; 2024 net sales growth guided to mid-to-high single digits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524189932/0001193125-24-189932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524189932/d866445d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-189932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer